Tarsa Therapeutics, Inc. — Form D
Tarsa Therapeutics, Inc. of PHILADELPHIA, PA, a company, filed a Form D exempt-offering notice with the SEC on 2017-01-13. The offering totals $1.6M, of which $1.6M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2017-01-13
- Form: D
- Accession: 0001475030-17-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $1.6M
- Amount sold: $1.6M
- Remaining: $33
- Investors: 5
- Date of first sale: 2016-12-29
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-278462
Issuer
- Name: Tarsa Therapeutics, Inc.
- CIK: 0001475030
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2009
- Address: 8 PENN CENTER, PHILADELPHIA, PA, 19103
- Phone: 267-273-7940
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| James Tananbaum | Director | South San Francisco, CA |
| Lewis Geffen | Executive Officer | Cambridge, MA |
| Richard Levy | Director | Chicago, IL |
| Eric Bednarski | Director | Boston, MA |
| Derek Ferguson | Director | New York, NY |
| Martin Edwards | Director | Boston, MA |
| Ashleigh Palmer | Director | Waltham, MA |
| RICHARD KOLLENDER | Director | LOWELL, MA |
| David Brand | Director | San Francisco, CA |
| David Brand | Executive Officer | San Francisco, CA |
| Gregory Lumpkin | Executive Officer | Philadelphia, PA |
| Matthew Rieke | Director | Philadelphia, PA |
Other filings by this issuer (7)
More